Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
Ulf Geisen, Dennis K Berner, Florian Tran, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1306-1311
Open Access | Times Cited: 344

Showing 1-25 of 344 citing articles:

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Victoria Furer, Tali Eviatar, Devy Zisman, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1330-1338
Open Access | Times Cited: 606
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, et al.
BMJ (2022), pp. e068632-e068632
Open Access | Times Cited: 390
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
Parakkal Deepak, Wooseob Kim, Michael Paley, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 11, pp. 1572-1585
Open Access | Times Cited: 289
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Rebecca H. Haberman, Ramin S. Herati, David Simón, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1339-1344
Open Access | Times Cited: 235
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Daniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1345-1350
Closed Access | Times Cited: 232
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
David Simón, Koray Taşçılar, Filippo Fagni, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1312-1316
Open Access | Times Cited: 180
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
Yolanda Braun‐Moscovici, Marielle Kaplan, Maya Braun, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1317-1321
Open Access | Times Cited: 179
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1744-1751
Open Access | Times Cited: 175
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
Anuraag Jena, Shubhra Mishra, Parakkal Deepak, et al.
Autoimmunity Reviews (2021) Vol. 21, Iss. 1, pp. 102927-102927
Open Access | Times Cited: 164
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 159
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
Laura Boekel, Maurice Steenhuis, Femke Hooijberg, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 11, pp. e778-e788
Open Access | Times Cited: 157
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
Heather Whitaker, Ruby S. M. Tsang, Rachel Byford, et al.
Journal of Infection (2022) Vol. 84, Iss. 5, pp. 675-683
Open Access | Times Cited: 156
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sebastian E. Sattui, Jean W Liew, Kevin Kennedy, et al.
RMD Open (2021) Vol. 7, Iss. 3, pp. e001814-e001814
Open Access | Times Cited: 150
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
Ron Ram, David Hagin, Nino Kikozashvilli, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 9, pp. 788-794
Open Access | Times Cited: 144
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
Parakkal Deepak, Wooseob Kim, Michael Paley, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 133
GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine
Ieva Čiučiulkaitė, Birte Möhlendick, Laura Thümmler, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 132
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV‐2 Vaccination
Peter Izmirly, Mimi Kim, Marie I. Samanovic, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 2, pp. 284-294
Open Access | Times Cited: 130
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
Jake A. Ruddy, Caoilfhionn M Connolly, Brian J. Boyarsky, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1351-1352
Open Access | Times Cited: 123
COVID‐19 vaccinations: The unknowns, challenges, and hopes
Kawthar Mohamed, Piotr Rzymski, Md Shahidul Islam, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1336-1349
Open Access | Times Cited: 119
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence
Sarah Wack, Timothy Patton, Laura K. Ferris
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 5, pp. 1274-1284
Open Access | Times Cited: 109
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
Clodoveo Ferri, Francesco Ursini, Laura Gragnani, et al.
Journal of Autoimmunity (2021) Vol. 125, pp. 102744-102744
Open Access | Times Cited: 109
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
Xue Li, Xinning Tong, Winnie Wan Yin Yeung, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 4, pp. 564-568
Open Access | Times Cited: 108
Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review
Kin Israel Notarte, Abbygail Therese Ver, Jacqueline Veronica Velasco, et al.
Critical Reviews in Clinical Laboratory Sciences (2022) Vol. 59, Iss. 6, pp. 373-390
Open Access | Times Cited: 88
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Page 1 - Next Page

Scroll to top